Life & Longevity Science Project

/in /da

The Life & Longevity Science Project represents a breakthrough in the field of personalized medicine and predictive diagnostics. It is promoted by SIEMPRE (Società Italiana Educazionale di Medicina di Precisione), an Italian scientific society committed to the advancement of biomedical research, education, and innovation in the field of Precision Medicine.

 

This project is based on the development of GEPAP, a Genetic–Epigenetic–Polymorphic–Analytical–Predictive Panel (Patent Pending), designed to offer a comprehensive and individualized diagnostic approach. GEPAP integrates genomic and epigenomic analysis with microbiome profiling, biochemical and metabolomic markers, and lifestyle-environmental data, to create a multidimensional map of an individual’s health status and disease risk profile.

 

Vision and Scientific Foundation

 

The Life & Longevity Science Project stems from a profound understanding of molecular individuality: each person’s genome is unique, with millions of genetic variations that determine how we respond to drugs, nutrients, environmental exposures, and even aging. Combined with recent advancements in epigenetics and omics sciences (such as metabolomics, lipidomics, proteomics, and microbiomics), this knowledge enables us to anticipate disease development and intervene early, before symptoms occur.

GEPAP (Patent Pending) is not just a genetic test. It is a holistic and dynamic system that evaluates:

Beyond Diagnosis: Targeted Treatment with Life & Longevity Science

In addition to providing early and personalized disease prediction, the Life & Longevity Science Project also proposes an innovative therapeutic approach based on Longevity Science principles. This strategy focuses on restoring and maintaining physiological function using endogenous biomolecules (patented), natural compounds produced by the body that play a crucial role in:

By harnessing these natural defense systems, the Life Science therapeutic protocol aims to complement the diagnostic precision of GEPAP with targeted, biocompatible, and personalized interventions, enhancing both health span and lifespan. This represents a concrete step toward a new generation of therapies, rooted in the biological intelligence of the human body.

Applications and Clinical Impact

GEPAP is a versatile tool designed for a wide range of applications:

This approach opens new frontiers in preventive medicine, providing with powerful tools to act in advance, shifting the paradigm from disease treatment to health preservation.

Economic and Social Value

According to health system data in Italy and Europe, adverse drug reactions and unnecessary treatments account for billions in avoidable healthcare costs each year. The GEPAP panel, by enabling targeted, effective, and safe interventions, has the potential to:

This makes GEPAP not only a scientific innovation, but a strategic asset for sustainable healthcare, especially relevant for countries investing in future-proof, patient-centered medical infrastructures.

Scientific Validation and Educational Mission

The Life Science Project is supported by an extensive body of research and international collaboration. SIEMPRE has gathered a multidisciplinary team of experts in genomics, epigenetics, clinical biochemistry, microbiology, and bioinformatics, to ensure scientific robustness and clinical applicability. Moreover, SIEMPRE is committed to education and dissemination, addressing the current gap in knowledge among healthcare professionals regarding precision medicine, pharmacogenomics, and omics sciences.

A Strategic Opportunity for Global Health Innovation

With the Life Science Project, SIEMPRE aims to export a fully scalable and customizable model of predictive medicine, adaptable to various healthcare systems and population needs. Its flexible design allows integration with local biobanks, diagnostic infrastructures, and national screening programs.

For investors and institutions looking to lead the transformation of medicine toward a more predictive, preventive, and personalized future, Life Science offers a concrete, science-driven, and socially impactful opportunity.

Precision medicine is not the future, it is the necessary evolution of healthcare.

And SIEMPRE is proud to be at the forefront of this transformation.

Farmagens Health Care

/in /da

Farmagens Health Care is a leading Italian company specializing in biotechnology research for Chronic Non-Communicable Diseases (NCDs) and in the research and development of innovative therapies, offering effective, safe, and personalized treatments in line with the principles of modern Precision Medicine. In 2016, Farmagens Health Care became the first company in the world to patent a signal molecule and transcription factor capable of positively influencing the homeostasis of the immune system, as well as biosynthesizing cannabinoids and other endogenous molecules. This breakthrough marked a significant milestone in biotechnology research within the sector.

This pioneering achievement serves as the foundation for the sustainable production of bioactive compounds, attracting global scientific interest. Farmagens Health Care’s current mission is to strengthen its leadership role and contribute to the advancement of Precision Medicine, expanding the therapeutic potential of Endogenous Biomolecules and endocannabinoids. The company is committed to promoting the Italian “Made in Italy” brand in scientific research.

At the “Rita Levi Montalcini Biotech Forum in Doha” on April 16-17, our goal is to seek international partnerships for the development of biotech research projects focused on therapeutic ALIAMIDES and other new Endogenous Molecules. The Farmagens delegation at the Forum will include CEO Augusto Sannetti, R&D team members Irene Palenca and Sara Rurgo, as well as Davide Della Morte Canosci, the Italian Society of Precision Medicine’s (S.I.E.M.PRE) expert from the University of Tor Vergata in Rome, who is also a Counselor to the Italian Minister of Health and the Minister of Scientific Research.

Farmagens Health Care’s objective at the Biotech Forum in Doha is to explore potential scientific collaborations in innovative therapies for metabolic and inflammatory diseases related to aging, with particular focus on pre-clinical and clinical research, and the industrial development of new therapeutic approaches for Non-Communicable Chronic Diseases (NCDs) With its expertise in Pharmacogenomics and Nutrigenomics, Farmagens Health Care possesses the most advanced knowledge in Europe on the Human Microbiome, thanks to proprietary studies, diagnostic methods, and patented biotechnological skills derived from next-generation sequencing (NGS) technology.

These advancements are carried out in collaboration with the associated laboratory “GENOMICA – Next Generation Genetics,” an advanced scientific unit of the Human Microbiome Care Research Institute (Clinical Advancement in Research and Education), an Italian Scientific Authority of the Italian Society of Precision Medicine (S.I.E.M.PRE). The “Human Microbiome” is a crucial endocrine organ that influences immune system function. Alterations in the microbiome increase the risk of developing various diseases.

Farmagens Health Care continues the research and development work initiated thirty years ago by Rita Levi Montalcini, the Italian Nobel Laureate in Medicine and Neuro-Science, who was the first to recognize the importance of lipid-based Endogenous Biomolecules involved in therapeutic pleiotropic activities. The Montalcini Global Biotech Forum in Doha presents an excellent opportunity to engage with public and private companies, learn about partnership opportunities, and explore collaboration with startups or research institutions involved in economic, commercial, and industrial exchanges with Farmagens Health Care.

Farmagens Health Care is Italy’s leading company in the research and development of innovative therapies represented by new Endogenous Biomolecules, which are the frontier of Biotechnology in the Medical sector. These therapies offer pharmaceutical companies, entrepreneurs, and investors opportunities for the production of endocannabinoid molecules and other Endogenous Biomolecules. These advances are highly competitive in terms of green sustainability, making the sector and entrepreneurial proposals particularly attractive for “Venture Capital” or “Private Equity Funds.”